NCT05152147 2026-02-27
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT06914011 2025-12-03
MRD2START
Asan Medical Center
Phase 3 Not yet recruiting
NCT06010303 2025-11-17
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 2 Active not recruiting
NCT07046221 2025-07-20
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT07019181 2025-06-13
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Not yet recruiting
NCT06692270 2025-02-28
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06646588 2024-10-17
SJZ-RMEEC01
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT05628610 2024-08-13
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT04776590 2024-04-12
CRISEC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Active not recruiting
NCT06061146 2023-12-26
TCRTOE
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting